Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

NEXT STORY
InnoSkel awarded Innovation Passport by the UK MHRA for the treatment of a rare bone disorder
PREV STORY
FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

REPEAT – World Renowned Physician Joins Core One Labs as Chief Medical Officer

author_avatar
NASDAQ Market News

OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

author_avatar
NASDAQ Market News

OpGen Reports First Quarter 2018 Financial Results and Provides a Business Update

Revenue increases 10% to $0.8 million, net loss decreases 39% to $3.0 million Conference ...

author_avatar
NASDAQ Market News